市場調査レポート
商品コード
1286006

ゲノム編集の世界市場 (2023~2030年):技術・デリバリー手法・モード・エンドユーザー別の規模・シェア・成長分析・予測

Global Genome Editing Market Size, Share, Growth Analysis, By Technology, By Delivery Method, By Mode, By End Use - Industry Forecast 2023-2030

出版日: | 発行: SkyQuest | ページ情報: 英文 157 Pages | 納期: 3~5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.40円
ゲノム編集の世界市場 (2023~2030年):技術・デリバリー手法・モード・エンドユーザー別の規模・シェア・成長分析・予測
出版日: 2023年04月02日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3~5営業日
  • 全表示
  • 概要
  • 目次
概要

ゲノム編集の市場規模は、2021年に48億1,104万米ドル、2022年に58億8,706万米ドルを示し、2023年から2030年にかけての予測期間中は22.3%のCAGRで推移し、2030年には360億6,095万米ドルの規模に成長すると予測されています。

ゲノム編集市場を牽引する要因としては、疾患やその他の遺伝性症状の有病率の増加、オーダーメイド薬への需要の高まり、R&D費の伸びとバイオテクノロジーおよび医薬品事業の開拓、民間および公的部門の資金調達の増加、シーケンシングの急速な進歩、ゲノム編集の発展などが挙げられます。

当レポートでは、世界のゲノム編集の市場を調査し、市場概要、市場への各種影響因子の分析、技術・イノベーションの動向、市場規模の推移・予測、各種区分・地域別の内訳、競合情勢、主要企業のプロファイルなどをまとめています。

目次

エグゼクティブサマリー

市場概要

親市場分析

市場概要

市場規模

  • 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
  • SWOT分析

主要市場洞察

  • 技術分析
  • 価格分析
  • サプライチェーン分析
  • バリューチェーン分析
  • 市場のエコシステム
  • IP分析
  • 貿易分析
  • スタートアップ分析
  • 原材料分析
  • イノベーションマトリックス
  • パイプライン製品の分析
  • マクロ経済指標

COVID-19の影響

  • 経済への影響- シナリオ評価
  • 市場規模の修正
  • 主要セグメントに対するCOVID-19の影響
  • 企業によるCOVID-19戦略

市場力学と見通し

  • 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
  • 規制状況
  • SWOT分析
  • ポーターの分析
  • 将来のディスラプションに関するSkyquestの特別な洞察
  • 世界のゲノム編集市場:技術別
  • メガヌクレアーゼ
  • CRISPR/CAS9・Talens/Megatals・Zfn
  • 世界のゲノム編集市場:デリバリー手法別
  • Ex-vivo
  • In-vivo
  • 世界のゲノム編集市場:モード別
  • 委託
  • 社内
  • 世界のゲノム編集市場:エンドユーザー別
  • バイオテクノロジー企業・製薬会社
  • 学術および政府研究機関
  • CRO

市場規模:地域別

  • 北米
  • 米国
  • カナダ
  • 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • その他の欧州
  • アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他のアジア太平洋
  • ラテンアメリカ
  • ブラジル
  • その他のラテンアメリカ
  • 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他の中東・アフリカ

主要企業プロファイル

  • トップ5社の比較
  • 主要企業の位置付け
  • 主要企業の採用戦略
  • 主要成功戦略
  • 市場における最近の活動
  • 主要企業の市場シェア
  • Merck KGaA
  • Cibus, Recombinetics, Inc.
  • Sangamo
  • Editas Medicine
  • Precision Biosciences
  • Ccispr Therapeutics
  • Intellia Therapeutics, Inc.
  • Caribou Biosciences, Inc.
  • Cellectis S.A.
  • AstraZeneca
  • Takara Bio USA
  • Horizon Discovery Group plc
  • Integrated DNA Technologies, Inc.
  • Egenesis Inc.
  • GenScript
  • New England Biolabs
  • OriGene Technologies, Inc.
  • Lonza
  • Thermo Fisher Scientific, Inc.
目次
Product Code: SQSG35J2001

Genome Editing Market size was valued at USD 4811.04 million in 2021 and is poised to grow from USD 5887.06 million in 2022 to USD 36060.95 million by 2030, growing at a CAGR of 22.3% in the forecast period (2023-2030).

A method for altering the DNA of a cell or an organism is genome editing. DNA sequences are cut during the procedure to add or remove DNA from the genome. The genome is modified to provide the cell the characteristics it requires. In order to support genome-altering research, numerous governments throughout the world are increasing their resources and grants. Due to the advantages of genome editing, governments are also funding public and commercial research as well as academic foundations to broaden the study of genome editing and hereditary designing. This results in the positive growth of the Genome Editing Market during the time of forecasting.

Factors driving the genome editing market include the increasing prevalence of disease and other hereditary conditions, growing demand for customised medications, growth in R&D spending and biotechnology and pharmaceutical business development, rise in private and public sector funding, rapid advances in sequencing, and developments in genome editing.

In recent years, the market has grown primarily due to the increased demand for synthetic genes in a range of biotechnology fields and the expanding use of CRISPR genome editing technology.

Due to the growing number of applications for genome editing tools, there is also more competition among market participants in the genome editing industry. More focus has been placed on the flexible CRISPR technology. For instance, Vertex Pharmaceuticals paid CRISPR Therapeutics USD 900 million in April 2021 for the development, production, and marketing of CRISPR-Cas9 gene-edited therapies for beta-thalassemia and sickle cell disease. These measures should accelerate the expansion of the genome editing market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Genome Editing Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report:

The Global Genome Editing Market is segmented based on Technology, Delivery Method, Mode, End-use, Application, and Region. Based on Technology it is categorized into CRISPR, TALEN, ZFN, Antisense, and Other Technologies. Based on the Delivery Method it is categorized into Ex-vivo and In-vivo. Based on Mode it is categorized into Contract, In-house. Based on End-use it is categorized into Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, and Contract Research Organizations. Based on the Region it is categorized into North America, Europe, Asia-Pacific, South America, and MEA.

Driver

In recent years, governments from many different nations have made large investments in the science of genomics, which has greatly aided the development of novel genome editing tools. In-depth genome engineering/editing research has also been made possible by the availability of government funding for university and government institutions. For instance, in March 2020, the Ministry of Innovation, Science, and Industry (Science) announced a USD 15 million grant to Genome Canada to fund 11 genomic research initiatives in the fields of health, agriculture, and the environment. These projects will receive a combined investment of USD 29.7 million from provincial governments, companies, and research partners. Among the initiatives is research into cervical and ovarian cancer. Due to large government investments in genomics, the number of genomics research programmes has expanded significantly. Therefore, growth in the genome editing market is anticipated during the course of the forecast period.

The market will grow due of how simple CRISPR/CAS9 is to employ. Compared to other methods of genome editing, this technology area is straightforward and reasonably priced.Through the application of gene editing technology, cancer can be treated with this method.

Restraint

Off-target effects of CRISPR-Cas9 are a significant worry. However, because Cas9 causes double-stranded breaks, any off-target nuclease activity can lead to changes in these genes, which may result in oncogenesis. When there are one to three mismatches in the target, CRISPR-Cas9 can tolerate them without producing off-target nuclease activity. The high frequency of off-target activity (50%)-mutations at locations other than the targeted on-target location-is another significant cause for concern. For instance, CRISPR can turn on the cancer-causing gene or target the genes that limit tumour growth. This adverse consequence has caused problems for numerous companies organising clinical trials. In order to increase the safety of this procedure, clinical studies have been stopped, and regulatory authorities are recommending more research.

The sophisticated features and functionality of genomic instruments are a key factor in their high price. It costs between $10 million and $20 million dollars. Pharmaceutical businesses and small- and medium-sized laboratories cannot afford the equipment at these high prices. It could be a significant barrier to the market's growth.

Market Trends

Major pharmaceutical, biotechnology, and genomic companies have all made investments in vaccine research and development as a result of the COVID-19 pandemic. The demand for vaccinations and potential antiviral treatments has brought genome editing/engineering technologies to the fore; these reasons are anticipated to propel the genome editing market in the years to come.

In comparison to traditional diagnostic or therapeutic approaches, molecular biology techniques like SHERLOCK, DETECTOR, CARVER and PAC-MAN based on CRISPR-Cas12/13, antisense peptide nucleic acids, ribozymes, aptamers, and RNAi silencing therapies, as well as antisense peptide nucleic acids, aptamers, and aptamers, proven crucial in COVID-19 outbreaks. Such aspects have emerged as significant drivers and are anticipated to propel the Genome Editing Market over the projected year. These technologies served as modern diagnostic and therapeutic approaches, from quicker and simpler diagnosis to more focused virus detection and elimination.

Table of Contents

Executive Summary

Market overview

  • Exhibit: Executive Summary - Chart on Market Overview
  • Exhibit: Executive Summary - Data Table on Market Overview
  • Exhibit: Executive Summary - Chart on Global Genome Editing Characteristics
  • Exhibit: Executive Summary - Chart on Market by Geography
  • Exhibit: Executive Summary - Chart on Market Segmentation
  • Exhibit: Executive Summary - Chart on Incremental Growth
  • Exhibit: Executive Summary - Data Table on Incremental Growth
  • Exhibit: Executive Summary - Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
  • Exhibit: Impact analysis of DROC, 2021
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
  • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
  • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
  • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
  • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
  • Exhibit: Parent Market Ecosystem Market Analysis
  • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
  • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
  • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
  • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
  • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
  • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
  • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy-scenario Assessment
  • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
  • Exhibit: Data Table on Global Genome Editing size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
  • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
  • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
  • Exhibit: Impact analysis of DROC, 2021
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
  • Regulatory Landscape
  • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
  • Competitive rivalry
  • Exhibit: Competitive rivalry Impact of key factors, 2021
  • Threat of substitute products
  • Exhibit: Threat of Substitute Products Impact of key factors, 2021
  • Bargaining power of buyers
  • Exhibit: buyers bargaining power Impact of key factors, 2021
  • Threat of new entrants
  • Exhibit: Threat of new entrants Impact of key factors, 2021
  • Bargaining power of suppliers
  • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
  • Political Impact
  • Economic impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact
  • Global Genome Editing by Technology
  • Market segments
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Data table on Market share 2021-2027 (%)
  • Meganucleases
  • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • (Crispr)/cas9, Talens/Megatals, Zfn)
  • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Global Genome Editing by Delivery Method
  • Market segments
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Data table on Market share 2021-2027 (%)
  • Ex-vivo
  • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • In-vivo
  • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Global Genome Editing by Mode
  • Market segments
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Data table on Market share 2021-2027 (%)
  • Contract
  • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • In-house
  • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Global Genome Editing by End-use
  • Market segments
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Data table on Market share 2021-2027 (%)
  • Biotechnology And Pharmaceutical Companies
  • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Academic And Government Research Institutes
  • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Contract Research Organizations
  • Market Estimates & Forecast, 2020-2027
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
  • Chart on Market share by country 2021-2027 (%)
  • Data Table on Market share by country 2021-2027(%)
  • USA
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Canada
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
  • Chart on Market share by country 2021-2027 (%)
  • Data Table on Market share by country 2021-2027(%)
  • Germany
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Spain
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • France
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • UK
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Rest of Europe
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
  • Chart on Market share by country 2021-2027 (%)
  • Data Table on Market share by country 2021-2027(%)
  • China
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • India
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Japan
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • South Korea
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Rest of Asia Pacific
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
  • Chart on Market share by country 2021-2027 (%)
  • Data Table on Market share by country 2021-2027(%)
  • Brazil
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Rest of South America
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
  • Chart on Market share by country 2021-2027 (%)
  • Data Table on Market share by country 2021-2027(%)
  • GCC Countries
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • South Africa
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Rest of MEA
  • Exhibit: Chart on Market share 2021-2027 (%)
  • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
  • Total number of companies covered
  • Exhibit: companies covered in the report, 2021
  • Top companies market positioning
  • Exhibit: company positioning matrix, 2021
  • Top companies market Share
  • Exhibit: Pie chart analysis on company market share, 2021(%)
  • Merck KGaA
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
  • Cibus, Recombinetics, Inc.
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
  • Sangamo
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
  • Editas Medicine
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
  • Precision Biosciences
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
  • Ccispr Therapeutics
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
  • Intellia Therapeutics, Inc.
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
  • Caribou Biosciences, Inc.
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
  • Cellectis S.A.
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
  • AstraZeneca
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
  • Takara Bio USA
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
  • Horizon Discovery Group plc
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
  • Integrated DNA Technologies, Inc.
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
  • Egenesis Inc.
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
  • GenScript
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
  • New England Biolabs
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
  • OriGene Technologies, Inc.
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
  • Lonza
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
  • Thermo Fisher Scientific, Inc.
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments